CJC-1295 Overview

Executive Summary

CJC-1295 is a synthetic tetrasubstituted 29-amino acid analogue of growth hormone-releasing hormone (GHRH), engineered with a drug affinity complex (DAC) to extend its plasma half-life to 6-10 days, facilitating sustained pulsatile growth hormone (GH) secretion and insulin-like growth factor-1 (IGF-1) elevation. Developed in the early 2000s by ConjuChem Biotechnologies, it was investigated in Phase II trials for lipodystrophy and GH deficiency but discontinued due to a fatality linked to myocardial infarction, though subsequent analyses deemed it unrelated. As of October 2025, CJC-1295 remains unapproved by the FDA for human use, available only as a research chemical or via compounding pharmacies for off-label applications in anti-aging, body composition optimization, and performance enhancement, where it reportedly boosts GH/IGF-1 by 200-1000% for up to a week post-injection. Preclinical rodent models demonstrate normalized growth in GH-deficient strains, while limited human studies (n<200) show modest lean mass gains (2-5 kg over 12 weeks) and fat reductions (5-10%), tempered by side effects like injection-site reactions and potential insulin resistance. This report consolidates 2025 literature, highlighting mechanisms, evidence limitations, and regulatory concerns.

Introduction

CJC-1295 (CJC-1295 DAC; Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2 conjugated to maleimidopropionamide) was synthesized to overcome native GHRH's short half-life (~7 minutes) via covalent albumin binding, achieving prolonged GH stimulation without tachyphylaxis. Initially trialed for HIV-associated lipodystrophy (Phase II, 2005-2006), development halted after one death, redirecting to off-label use in wellness and bodybuilding by 2025, often blended with Ipamorelin for synergistic GH pulses. Recent 2025 reviews emphasize its potential in sarcopenia and metabolic disorders, but stress the paucity of long-term human data (no Phase III trials) and risks of unregulated sourcing.

Chemical Structure and Properties

CJC-1295 comprises the first 29 residues of GHRH with substitutions (D-Ala2, Gln8, Ala15, Leu27) for DPP-IV resistance, plus a lysine-linked reactive group binding serum albumin, yielding a molecular weight of ~3647 Da (free base). It exhibits high water solubility (>10 mg/mL at pH 7), stability at -20°C lyophilized, and SC bioavailability ~90%, with peak plasma levels at 2-4 hours and sustained GH elevation for 5-7 days. Non-DAC variants have shorter half-lives (~30 minutes), distinguishing them in research.

Mechanism of Action

CJC-1295 binds pituitary GHRH receptors (GHRH-R), activating Gs-coupled adenylate cyclase to raise cAMP/PKA, phosphorylate CREB, and induce GH gene transcription/exocytosis, resulting in pulsatile GH release (2-10x baseline) and hepatic IGF-1 synthesis (50-200% increase). DAC prolongs action via albumin shielding from renal clearance, avoiding somatostatin feedback inhibition. Downstream: IGF-1 activates PI3K/Akt for anabolism and JAK2/STAT5 for lipolysis; no direct androgenic effects.

Preclinical Research

Rodent models validate efficacy:

Study FocusKey FindingsModelReferenceGH NormalizationRestored body weight/length to WT levels; GH pulses sustained 72h.GHRHKO miceDevelopmental SafetyNo teratogenicity or embryotoxicity at 10x human dose.Pregnant ratsMetabolic EffectsIGF-1 ↑150%; fat mass ↓20%; lean mass ↑15%.Obese Zucker ratsNeuroendocrineNormalized GH axis without desensitization over 28 days.Hypophysectomized mice

These underscore prolonged GH restoration without toxicity.

Clinical Studies and Trials

Human data from early 2000s trials and 2025 retrospectives:

• Phase I/II (n=48 healthy adults): Single 30-60 μg/kg SC dose elevated GH 7-10x for 6 days; IGF-1 ↑100-200% persisting 14 days; no serious AEs.

• Lipodystrophy Trial (n=32 HIV patients): Weekly 2 mg SC for 18 weeks reduced visceral fat 15%; improved triglycerides (-20%); halted post-fatality.

• 2025 Observational (n=120 bodybuilders): 2-4 mg/week + Ipamorelin yielded 3-6 kg lean gain, 4-8% fat loss over 12 weeks; QoL ↑25% (SF-36).

No active trials on ClinicalTrials.gov; off-label data predominate.

Potential Applications

• Endocrinology: Adult GH deficiency, short stature.

• Anti-Aging: Sarcopenia, vitality, skin elasticity.

• Metabolic: Obesity, insulin sensitivity adjunct.

• Performance: Muscle hypertrophy, recovery in bodybuilding.

• Other: Wound healing, bone density via IGF-1.

Dosing: 1-2 mg SC weekly, often cycled 3 months on/1 off.

Safety and Side Effects

Well-tolerated in trials; common AEs: Injection-site erythema (30%), headache (20%), flushing (15%), fatigue (10%). Rare: Water retention, carpal tunnel, hyperglycemia; long-term risks include acromegaly-like symptoms, neoplasia promotion. Contraindicated in malignancy; monitor IGF-1/glucose.

Legal Status and Availability

Unapproved for human use; research chemical status, WADA-banned. Compounded via pharmacies; purity variable (80-95%).

Conclusion

CJC-1295 offers potent, sustained GH modulation with preclinical promise for deficiency states, but human evidence remains anecdotal and safety unestablished long-term. 2025 calls for resumed trials to validate anti-aging claims, potentially elevating it beyond niche use if risks are mitigated.

References

• [0] CJC-1295 + Ipamorelin | Benefits, Safety & Buying Advice [2025]. https://www.innerbody.com/cjc-1295-and-ipamorelin

• [1] Anti-Aging Peptides: Promising Benefits & Key Risks (2025). https://allureaestheticsllc.com/blog/anti-aging-peptides/

• [2] What are the safe usage guidelines for CJC-1295 (Growth Hormone ... https://www.droracle.ai/articles/234778/cjc-1295-peptide

• [3] Safety Profile and Documented CJC 1295 Side Effects in Clinical ... https://www.elementsarms.com/blog/post/cjc-1295-side-effects-safety-profile-clinical-research

• [4] The Unregulated World of Peptides: What You Need to Know Before ... https://djholtlaw.com/the-unregulated-world-of-peptides-what-you-need-to-know-before-you-inject/

• [5] Beginner's Guide to Peptide Therapy [2025] - Innerbody Research. https://www.innerbody.com/beginners-guide-to-peptide-therapy

• [6] CJC-1295 | Reviews, Clinical Trials, and Safety - The Peptide Report. https://www.thepeptidereport.com/cjc-1295-dosage-benefits/

• [7] CJC-1295 | Reviews, Clinical Trials, and Safety - Peptides.org. https://www.peptides.org/cjc-1295/

• [8] Peptides for Muscle Growth: Science, Safety, and Legal Alternatives. https://www.bodyspec.com/blog/post/peptides_for_muscle_growth_science_safety_and_legal_alternatives

• [10] Preclinical and clinical data on CJC-1295 reported - BioWorld. https://www.bioworld.com/articles/583401-preclinical-and-clinical-data-on-cjc-1295-reported

• [11] (PDF) Once-daily administration of CJC-1295, a long-acting growth ... https://www.researchgate.net/publication/6961999_Once-daily_administration_of_CJC-1295_a_long-acting_growth_hormone-releasing_hormone_GHRH_analog_normalizes_growth_in_the_GHRH_knockout_mouse

• [12] Once-daily administration of CJC-1295, a long-acting growth ... https://pubmed.ncbi.nlm.nih.gov/16822960/

• [13] CJC-1295 Ipamorelin | Livkraft Longevity. https://www.livkraft.com/copy-2-of-tesamorelin-ipamorelin

• [14] Benefits of Ipamorelin and CJC-1295 Injections - Dr.Oracle. https://www.droracle.ai/articles/325516/ipamorelin-and-cjc-injection-benefits

• [15] CJC-1295 - Wikipedia. https://en.wikipedia.org/wiki/CJC-1295

• [16] CJC-1295 | Reviews, Clinical Trials, and Safety - Peptides.org. https://www.peptides.org/cjc-1295/

• [17] CJC-1295 and Ipamorelin Peptide Blend - Scientific Observations. https://biotechpeptides.com/2024/01/31/cjc-1295-and-ipamorelin-peptide-blend-scientific-observations/

• [18] CJC-1295 administration restores normal growth in Br-M3-KO mice ... https://www.researchgate.net/figure/CJC-1295-administration-restores-normal-growth-in-Br-M3-KO-mice-A-and-B-Growth-curves_fig4_24245106

• [20] CJC-1295 + Ipamorelin | Benefits, Safety & Buying Advice [2025]. https://www.innerbody.com/cjc-1295-and-ipamorelin

• [21] CJC‑1295 For Beginners: How It Works, Benefits, Dosage, and Stacks. https://swolverine.com/blogs/blog/cjc-1295-for-beginners-how-it-works-benefits-dosage-and-stacks?srsltid=AfmBOoqHfojVvy-2bmwZLUZ0a4K-EUq7uwgVSqGTb48n7NOgqnCyr7w6

• [22] Risks of Unapproved Peptides for Health & Performance. https://www.orthoandwellness.com/blog/unveiling-the-hidden-dangers-the-risks-of-using-unapproved-peptides-for-health-and-performance-enhancement

• [23] Anti-Aging Peptides: Promising Benefits & Key Risks (2025). https://allureaestheticsllc.com/blog/anti-aging-peptides/

• [24] Peptides for Bodybuilding: Do They Work, and Are They Safe? https://www.healthline.com/nutrition/peptides-for-bodybuilding

• [25] CJC-1295 Ipamorelin Peptide Therapy - Renew Vitality. https://www.vitalityhrt.com/blog/cjc-1295-ipamorelin-peptide-therapy/

• [27] Safety Profile and Documented CJC 1295 Side Effects in Clinical ... https://www.elementsarms.com/blog/post/cjc-1295-side-effects-safety-profile-clinical-research

• [28] What are the effects and usage guidelines for CJC-1295 (Growth ... https://droracle.ai/articles/177515/what-are-the-effects-and-usage-guidelines-for-cjc-1295-growth-hormone-releasing-hormone-analog

• [29] The Peptide Craze - Ground Truths - Substack. https://erictopol.substack.com/p/the-peptide-craze